Sulfonylurea

Phase 3 trial demonstrates the safety and efficacy of albiglutide in type 2 diabetes patients with renal impairment…. Renal impairment is a common comorbid condition in type 2 diabetes patients with reported incidence rates as high as 35%. Those with renal insufficiency often find their diabetes treatment options limited. Possible …

Besides sulfonylureas, GLP-1RA can also be a treatment option for HNF1A diabetic patients…. Maturity-onset diabetes of the young adults (MODY) is responsible for 1-2% of all cases of diabetes. HNF1A diabetes is caused by loss of B-cell functions. It is usually misclassified as type 1 diabetes due to common hyperglycemic …

Dr. Stanley Schwartz introduces himself briefly and talks about how much he enjoying his “working retirement” and actually get more academic work done since he left academia. He also says that he is “having great fun taking care of my patients and advacning the ideas I come up with as …

Dr. Stanley Schwartz talks about his groundbreaking presentation at the 2014 ADA in which he outlined a new approach to classifying diabetes based on the health of the patient’s beta-cells. He explains in detail here how the current system of classification is full of contradictions and overlap between different types …

Dr. Stanley Schwartz talks about choosing the right drugs for each individual patient, and which ones should be first tier choices, which ones second, and the efficacy we should be looking for from them….   More videos in this series with Dr. Schwartz Stanley Schwartz, MD, FACP, FACE: Introduction, ADA …

Dr. Stanley Schwartz relates his overwhelmingly positive experience treating patients with newer drug therapies such as GLP-1 agonists and SGLT-2 inhibitors. He explains that he will sometimes put patients, on the very first day of their visit, on these medications when their A1c’s are very high and, one month later, …

Dr. Stanley Schwartz talks about why he doesn’t think that sulfonylureas should be used any longer, emphasizing that although they were useful when there were no alternatives, there are far safer and better drugs available today. More videos in this series with Dr. Schwartz Stanley Schwartz, MD, FACP, FACE: Introduction, …

Dr. Stanley Schwartz talks about the best way to determine beta cell function and says that there are actually several indicators that might need to be used. He suggests that there may be several steps that need to be taken including genotyping patients, looking at both classic markers and newer …

Dr. Stanley Schwartz talks about addressing the epidemic of not only diabetes but the growing numbers of prediabetes patients. He reviews the current policy situation and then talks about how he proceeds in his practice with prediabetes patients.  He points out that several studies have shown that adding certain medications …

  Dr. Stanley Schwartz addresses the question of, “Where do we go from here?” regarding the beta-cell centric approach. He notes that there are two ways to approach the question — grassroots and a top-down approach — and says that both avenues should be pursued. He hopes that his his …